Nectar Lifesciences (NecLife) today got an approval from Korean Food and Drug Administration (KFDA) for Cefuroxime Axetil (Amorphous). The company expects business potential worth $10 billion in South Korea for the approved molecule.
South Korean pharmaceuticals market size is $16.5 billion and is expected to increase to $21.2 billion by 2011.
Dinesh Dua, CEO and director, NecLife said: "This approval is in-line with our strategy of having grater presence in regulated markets. We can further augment our position in the cephalosporin market." Cephalosporin is one of the broad spectrum antibiotic obtained from fungi and is related to penicillin.
NecLife is one of the largest producers of cephalosporin, present in 50 countries. It offers oral and sterile cephalosporin and semi-synthetic active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs). The company is growing its presence in empty hard gelatine capsules (EHGCs) and menthol products.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app